Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28827287 | 0.89 | ALDH1A1 (0.50) | ALDH1A1NPC1MEN1LMNAKMT2A | |
| SCHEMBL3312608 | 0.89 | ALDH1A1 (0.50) | ALDH1A1NPC1MEN1LMNAKMT2A | |
| SCHEMBL15966242 | 0.86 | ALDH1A1 (0.41) | ALDH1A1NPC1MEN1LMNAKMT2A | |
| SCHEMBL14314946 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MEN1LMNAKMT2ATSHR | |
| SCHEMBL10416209 | 0.81 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL10416207 | 0.81 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL942936 | 0.80 | ALDH1A1 (0.44) | ALDH1A1MEN1LMNAKMT2AL3MBTL1 | |
| SCHEMBL19102522 | 0.77 | ALDH1A1 (0.41) | ALDH1A1TSHRCA12CA2CA9 | |
| SCHEMBL10174084 | 0.77 | ALDH1A1 (0.41) | ALDH1A1NPC1LMNAGAARAB9A | |
| SCHEMBL15966239 | 0.77 | ALDH1A1 (0.41) | ALDH1A1LMNAGAAL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765305-A4 | CONTROLLED PHASE COMPOSITION TECHNOLOGY AS AN IMPROVED PROCESS FOR PROTECTION OF DRUGS | DRUGTECH CORP (US) | 2008-06-04 | — | — | EP | claimed |
| EP-0758244-B2 | CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN | PFIZER (US) | 2008-02-13 | — | — | EP | claimed |
| EP-1765305-A1 | CONTROLLED PHASE COMPOSITION TECHNOLOGY AS AN IMPROVED PROCESS FOR PROTECTION OF DRUGS | Drugtech Corporation (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2006017159-A1 | CONTROLLED PHASE COMPOSITION TECHNOLOGY AS AN IMPROVED PROCESS FOR PROTECTION OF DRUGS | DRUGTECH CORPORATION (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060008527-A1 | Controlled phase composition technology as an improved process for protection of drugs | PARTICLE DYNAMICS INTERNATIONAL, LLC | 2006-01-12 | — | — | US | claimed |
| US-20020044965-A1 | Controlled- release dosage forms of azithromycin | CURATOLO WILLIAM J (US) | 2002-04-18 | — | — | US | claimed |
| EP-0758244-B1 | CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN | PFIZER (US) | 2001-11-28 | — | — | EP | claimed |
| US-6068859-A | AZITHROMYCIN AND A CARRIER WHICH RELEASES AZITHROMYCIN AT SPECIFIC DOSAGES AFTER TIME INTERVALS AFTER INGESTION; SIDE EFFECT REDUCTION | PFIZER INC. (US) | 2000-05-30 | — | — | US | claimed |
| EP-0758244-A1 | CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN | PFIZER INC. (US) | 1997-02-19 | — | — | EP | claimed |
| WO-1995030422-A1 | CONTROLLED-RELEASE DOSAGE FORMS OF AZITHROMYCIN | PFIZER INC. (US) | 1995-11-16 | — | — | WO | claimed |
| US-5032572-A | Drug delivery | MEDICAL COLLEGE OF OHIO (US) | 1991-07-16 | — | — | US | claimed |
| US-4931432-A | Dietary vaccine for inhibiting metabolism of methanol | MONTE WOODROW C (US) | 1990-06-05 | — | — | US | claimed |
| US-4834981-A | Dietary vaccine for inhibiting metabolism of methanol | MONTE WOODROW C (US) | 1989-05-30 | — | — | US | claimed |
| US-4663308-A | Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointestinal tract | MEDICAL COLLEGE OF OHIO (US) | 1987-05-05 | — | — | US | claimed |
| US-12091428-B1 | Chemoselective hydrogenation of α,β-unsaturated ketone and polyelectrochromism of electronically weakly coupled 4,4′-divinylazoarylene-bridged diruthenium complex bearing two Ru(CO)(2-hydroxyquinolato(PiPr3)2 moieties | King Faisal University (SA) | 2024-09-17 | — | — | US | disclosed |
| US-11986810-B1 | Selective reduction catalyst of α,β-unsaturated ketone using electronically weakly coupled 4,4′-divinylazoarylene-bridged diruthenium complex bearing two Ru(CO)(8-mercaptoquinolato(PiPr3)2 moieties | King Faisal University (SA) | 2024-05-21 | — | — | US | disclosed |
| US-11987596-B1 | Polyelectrochromism of electronically weakly coupled 4,4′-divinylazoarylene-bridged two Ru(CO)Cl(PiPr3)2 entities | King Faisal University (SA) | 2024-05-21 | — | — | US | disclosed |
| US-4834981-A | Dietary vaccine for inhibiting metabolism of methanol | MONTE WOODROW C (US) | 1989-05-30 | — | — | US | disclosed |
| US-4663308-A | Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointestinal tract | MEDICAL COLLEGE OF OHIO (US) | 1987-05-05 | — | — | US | disclosed |
| US-4663308-A | Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointestinal tract | MEDICAL COLLEGE OF OHIO (US) | 1987-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091428-B1 | Chemoselective hydrogenation of α,β-unsaturated ketone and polyelectrochromism of electronically weakly coupled 4,4′-divinylazoarylene-bridged diruthenium complex bearing two Ru(CO)(2-hydroxyquinolato(PiPr3)2 moieties | DHCR24, PI4K2A, PIP4K2A | ALDH1A1 2799/4885NPC1 4307/4885MEN1 4127/4885 |
| US-11987596-B1 | Polyelectrochromism of electronically weakly coupled 4,4′-divinylazoarylene-bridged two Ru(CO)Cl(PiPr3)2 entities | BICRA, LIG3, PIP4K2A | ALDH1A1 4143/4885NPC1 4693/4885MEN1 2486/4885 |
| US-11986810-B1 | Selective reduction catalyst of α,β-unsaturated ketone using electronically weakly coupled 4,4′-divinylazoarylene-bridged diruthenium complex bearing two Ru(CO)(8-mercaptoquinolato(PiPr3)2 moieties | PI4K2B, DHCR24, PI4K2A | ALDH1A1 1919/4885NPC1 3451/4885MEN1 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.